BioAsia was elected as the Vice President Unit of the Shanghai Health Industry Development Promotion Association, a professional organization of voluntary members from health industry-related units and enterprises, under the supervision of the Shanghai Municipal Commission of Economy and Informatization.
Professor Chen Zhu'an, renowned as the "Father of Chanhua," officially joined BioAsia to work alongside the company's expert team in advancing the vision of human health and wellness.
The Group established its first R&D center—the Shanghai BioAsia Life Science Research Institute—at the National University Science Park of the University of Shanghai for Science and Technology. This marked the company's official transition from the real estate industry to the health industry, embarking on an entrepreneurial journey in life sciences and biopharmaceuticals.
BioAsia Biotech CO., LTD. established its industrial base in the Pinghu Economic Development Zone, Zhejiang, marking the company's industrialization of scientific research achievements on Chanhua (Cordyceps cicadae).
This professional popular science museum dedicated to Cordyceps has been awarded the titles of Cordyceps Popular Science Education Demonstration Base, Cordyceps R&D Promotion Demonstration Base, Cordyceps cicadae Industrialization Demonstration Base and Cordyceps Application Achievement Promotion Base by China National Center for TCM Science and Technology Development under the National Administration of Traditional Chinese Medicine. It was rated a national AA-level scenic spot upon opening and upgraded to AAA level in 2016.
With the approval of Zhejiang Provincial Department of Human Resources and Social Security, BioAsia successfully established a provincial-level Postdoctoral Research Station.
The site is Located in Qingjiangpu District, Huai'an City, Jiangsu Province, with an investment of RMB 60 million and spanning over 680 mu of land, establishing a solid foundation for large-scale farming.
BioAsia wholly acquired Plantamed AB in Sweden, establishing a "bridgehead" for overseas expansion. Its new product Cikaria (Chanhua Cordyceps tablets) was unveiled at the 2018 World Cordyceps Forum.
In December 2018, BioAsia's patent "A Strain of Paecilomyces cicadae and Its Application" (Patent No.: ZL201110120603.1) was awarded the "China Patent Gold Award" jointly issued by the China National Intellectual Property Administration and the World Intellectual Property Organization.
Professor Li Zengzhi, Chief Scientist of BioAsia, and Professor Chen Zhu'an, Chief Microbiologist of BioAsia, were both awarded the "Republic Commemorative Medal" on the 70th anniversary of the founding of the People's Republic of China.
The Chanhua (Cordyceps cicadae) originally developed by BioAsia was approved as a "Novel Food Ingredient" by the National Health Commission of China.
BioAsia's artificially cultivated Chanhua (Cordyceps cicadae) fruiting bodies were granted the "New Plant Variety Protection."
Zhejiang BioAsia Biopharmaceutical Co., Ltd. was renamed to " BioAsia Biotech CO., LTD." — elevating the company from a regional entity to a national enterprise.